RA Capital Management

Develops oligonucleotide therapeutics targeting chronic hepatitis B

Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases

Develops human-derived antibody therapeutics for atopic dermatitis and inflammatory disease

Develops fungal genome-derived therapeutics for organ transplant rejection

Develops treatments for serious respiratory diseases

Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD

Develops broad-spectrum antiviral prophylactic therapies for respiratory infections

Develops hormonal and non-hormonal male contraceptives for men and couples globally

Clinical-stage company developing neonatal cardiac progenitor cell therapies for Duchenne-associated cardiomyopathy

Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma

Develops highly targeted, small molecule medicines for cancer and rare diseases

Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment

Provides CAR-T and other advanced treatment delivery in community outpatient settings

Advancing next-generation therapeutics for migraine and other headache disorders

Developing a next-generation pertussis vaccine candidate BPZE1

Develops modular compact fusion machines for clean energy applications

Develops inhaled therapies for severe respiratory diseases

Develops medicines targeting historically undruggable protein targets in cancer